Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone732-524-0400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$81.58 billion
Profitability
Miscellaneous
Employees134,000
OptionableOptionable
Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson announced a quarterly dividend on Wednesday, January 2nd. Investors of record on Tuesday, February 26th will be given a dividend of $0.90 per share on Tuesday, March 12th. This represents a $3.60 dividend on an annualized basis and a yield of 2.64%. The ex-dividend date is Monday, February 25th. View Johnson & Johnson's Dividend History.
How will Johnson & Johnson's stock buyback program work?
Johnson & Johnson announced that its board has approved a stock buyback plan on Monday, December 17th 2018, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 1.5% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Tuesday, January, 22nd. The company reported $1.97 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.02. The firm had revenue of $20.39 billion for the quarter, compared to the consensus estimate of $20.27 billion. Johnson & Johnson had a return on equity of 35.09% and a net margin of 18.75%. The firm's quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.74 earnings per share. View Johnson & Johnson's Earnings History.
When is Johnson & Johnson's next earnings date?
How can I listen to Johnson & Johnson's earnings call?
Johnson & Johnson will be holding an earnings conference call on Tuesday, April 16th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson updated its FY19 earnings guidance on Tuesday, January, 22nd. The company provided earnings per share (EPS) guidance of $8.50-8.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.60. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $82.74 billion.Johnson & Johnson also updated its FY 2019 guidance to $8.50-8.65 EPS.
What price target have analysts set for JNJ?
13 analysts have issued twelve-month price targets for Johnson & Johnson's shares. Their predictions range from $129.00 to $160.00. On average, they expect Johnson & Johnson's share price to reach $141.8182 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
What is the consensus analysts' recommendation for Johnson & Johnson?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Johnson & Johnson.
Has Johnson & Johnson been receiving favorable news coverage?
Press coverage about JNJ stock has been trending somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Johnson & Johnson earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG).
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Mr. Alex Gorsky, Chairman & CEO (Age 59)
- Dr. Paulus A. Stoffels, Vice Chairman of Exec. Committee, Exec. VP & Chief Scientific Officer (Age 57)
- Mr. Joaquin Duato, Vice Chairman of Exec. Committee, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 56)
- Mr. Joseph J. Wolk CPA, Exec. VP & CFO
- Mr. Ronald A. Kapusta, Controller & Chief Accounting Officer (Age 60)
Who are Johnson & Johnson's major shareholders?
Johnson & Johnson's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.82%), Oregon Public Employees Retirement Fund (2.79%), Geode Capital Management LLC (1.36%), Northern Trust Corp (1.30%), Bank of New York Mellon Corp (1.20%) and Massachusetts Financial Services Co. MA (1.08%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Which major investors are selling Johnson & Johnson stock?
JNJ stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Bessemer Group Inc., Brandywine Global Investment Management LLC, Massachusetts Financial Services Co. MA, Voloridge Investment Management LLC, Canada Pension Plan Investment Board, Boston Partners and HM Payson & Co.. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.
Which major investors are buying Johnson & Johnson stock?
JNJ stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp, California Public Employees Retirement System, Comgest Global Investors S.A.S., Legal & General Group Plc and Mn Services Vermogensbeheer B.V.. View Insider Buying and Selling for Johnson & Johnson.
How do I buy shares of Johnson & Johnson?
Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of JNJ stock can currently be purchased for approximately $136.38.
How big of a company is Johnson & Johnson?
Johnson & Johnson has a market capitalization of $365.89 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.
What is Johnson & Johnson's official website?
How can I contact Johnson & Johnson?
Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
